Botanix Pharmaceuticals (ASX:BOT) said that the commercial launch of its lead dermatology product, Sofdra, a topical gel for treating excessive underarm sweating, remains "on track," according to a Monday filing with the Australian bourse.

The company's sales team is performing in line with expectations, and the full digital launch expected this month will further drive prescription volume, per the filing.

Growth in new patient prescriptions is also on track, with refill rates exceeding targets, the filing added.

The company also said it does not expect any material impact from tariffs on Sofdra.